Introduction
The p53 homologue p73 has been mapped to chromosome 1p36.3, a locus known to be subject to recurrent loss of heterozygosity (LOH) in various human cancers. 1 At least seven transactivation (TA)-competent isoforms of p73 exist that have different C-termini (TA-p73, i.e. a (full-length), b, g, d, e, Z and z) and cooperate via heterodimerization to regulate TA of genes that become induced after exposure to DNA-damaging agents. [2] [3] [4] [5] [6] [7] [8] [9] Several of these target genes are shared with p53, suggesting that p73 plays a role in cellular responses to DNA damage, for example, cell cycle arrest, DNA repair and apoptosis. In contrast to p53 that is mutated in more than 50% of human cancers, a genetically or epigenetically changed p73 gene is less common in tumours. This suggests that p73 is not a classical tumour suppressor gene and may have different functions than p53. 10 The discovery of an N-terminally truncated isoform of human p73, DN-p73, shed new light on its function. 5 DN-p73 is transactivation-deficient (DTA) and capable of suppressing p53-and p73-mediated TA. 5, 11 In response to DNA damage, expression of DN-p73 is induced from two different transcripts (DN-p73 and DN 0 -p73) to create a dominant-negative feedback loop that regulates the function of both p53 and TA-p73. 5, [12] [13] [14] Like mutant p53, DN-p73 is thought to exhibit oncogenic or antiapoptotic potential. In addition to DN-p73 several other Nterminally truncated isoforms have been identified, which lack exon 2 (p73Dex2), exon 3 (p73Dex3) or both (p73Dex2/3). 11, [15] [16] [17] Mutant p53 or N-terminally truncated p73 may cause resistance to anticancer agents through inhibition of wild-type p53 and TA-p73. [18] [19] [20] [21] The T-lineage phenotype of childhood acute lymphoblastic leukaemia (ALL) is associated with an increased relapse-risk and in vitro resistance to drugs as compared to a precursor B phenotype. 22 The frequency of p53 mutations in haematological malignancies is relatively low compared to other tumours, particularly in childhood ALL cases, where mutations occur in less than 5% of patients at initial diagnosis. 10, [23] [24] [25] Myeloid leukaemia and chronic lymphocytic leukaemia are often characterized by deregulation of p73 gene expression, but no studies have been reported on p73 in T-ALL. [26] [27] [28] [29] [30] [31] p73 is known to be activated by DNA-damaging chemotherapeutic agents such as doxorubicin, cisplatin, camptothecin and gemcitabine. 18, 32 To date, no distinction between various isoforms of p73 has been made in childhood T-ALL nor has it been investigated whether expression of these isoforms might affect drug sensitivity or outcome in these patients. Therefore, we investigated whether proapoptotic (TA-p73, i.e. total of TA isoforms) or antiapoptotic isoforms of p73 (DTA-p73, i.e. p73Dex2, p73Dex3, p73Dex2/3, DN-p73 and DN 0 -p73) are differentially expressed in childhood T-ALL compared to normal cells and whether their expression is related to clinical outcome and resistance to the DNA-damaging drug daunorubicin which is used in the treatment of childhood ALL.
Materials and methods

Patient samples
Bone marrow or peripheral blood samples were obtained from 55 paediatric T-ALL patients at presentation after obtaining informed consent from the patients themselves or their legal guardians, according to the Helsinki declaration. Leukaemic cells were isolated by density gradient centrifugation at 480 g for 15 min (Lymphoprep, 1.077 g/ml; Lucron Bioproducts B.V., Gennep, The Netherlands) and collected mononuclear cells were washed twice with RPMI 1640/1% fetal calf serum and resuspended in RPMI 1640 complemented with 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 0.125 mg/ml fungizone, 0.2 mg/ml gentamycin (Invitrogen/Life Technologies, Merelbeke, Belgium), 20% fetal calf serum (Integro), 5 mg/ml insulin, 5 mg/ml transferrin and 5 ng/ml sodium selenite (Sigma, Zwijndrecht, The Netherlands). If necessary, the percentage of leukaemic cells was enriched to 490% by removal of contaminating cells using immunomagnetic beads. 33 Patient samples were collected from the Dutch Childhood Oncology Group (DCOG) and the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukaemia (COALL). The patients had an age range of 1.8-15.4 years and a median age of 7.3 years. In this study group, 30 children were treated according to the DCOG ALL protocols and 25 children were treated according to the COALL-97 protocol. Thirty-eight patients were in continuous complete remission with a median follow-up time of 5.2 years (follow-up range 1.3-11.6 years). Eleven patients experienced a relapse (occurring between 0.6 and 3.2 years after diagnosis, median 1.0 years), five patients who entered complete remission died of toxicity of treatment and one patient did not enter complete remission. Nonleukaemic mononuclear cells of bone marrow were obtained from 12 nonleukaemic paediatric patients and of peripheral blood of five volunteering adults.
MTT assay
The in vitro sensitivity of leukaemic cells to prednisolone (Prednisolone sodium phosphate, Bufa B.V., Uitgeest, The Netherlands), vincristine (Vincristinesulphate-TEVA, TEVA), L-asparaginase (Paronal, Christiaens B.V., Breda, The Netherlands) and daunorubicin (Cerubidine, Aventis, Hoevelaken, The Netherlands) was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay as described before. 33, 34 Briefly, 100 ml aliquots of cell suspension with a density of 1.6 Â 10 6 viable cells/ml were incubated with six concentrations of each cytostatic drug, ranging from 250 to 0.007 mg/ml for prednisolone, 50 to 0.049 mg/ml for vincristine, 10 to 0.003 IU/ml for L-asparaginase and 2 to 0.002 mg/ml for daunorubicin. After 4 days at 371C, the quantity of viable cells was measured spectrophotometrically at 562 nm after the addition of 10 ml MTT (5 mg/ml; Sigma) followed by 6 h incubation at 371C and subsequent addition of 100 ml acidified isopropanol (0.04 M HCl-isopropanol). The LC 50 for each drug was calculated as the concentration at which OD 562 of the treated leukaemic cell population was 50% of the OD 562 measured for the untreated cell population (adjusted for blank values).
DNA and RNA extraction
Genomic DNA and total RNA were isolated from at least 5 Â 10 6 cells in TRIzol (Invitrogen/Life Technologies) according to the manufacturer's protocol, except for minor modifications concerning the RNA extraction. An additional phenol-chloroform extraction was performed and the isopropanol precipitation at À201C was facilitated by the addition of 1 ml glycogen (20 mg/ml; Roche, Almere, The Netherlands). Subsequently, RNA pellets were dissolved in 20 ml RNAse-free TE-buffer (10 mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid (EDTA), pH ¼ 8.0) and stored at À801C. DNA pellets were dissolved in 100 ml TE-buffer and stored at 41C.
Real-time quantitative polymerase chain reaction cDNA was synthesized using random hexamers and oligo dT as previously reported. 35 The mRNA levels of TA-p73 (i.e. total of TA isoforms) and DTA-p73 (i.e. p73Dex2, p73Dex3, p73Dex2/3 and DN-p73 and DN 0 -p73) were measured by real-time quantitative polymerase chain reaction (PCR) and was expressed relatively to the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Sequences and positions of primers and dual-labelled probes used for the detection of p73 isoforms are shown in Table 1 and Figure 1 , respectively.
PCR reactions were carried out in volumes of 50 ml containing 40 ng cDNA, 1 Â Taqman buffer A, 4 mM MgCl 2 (Applied Biosystems, Nieuwerkerk a.d. IJssel, The Netherlands), 200 mM of each dNTP (GE Healthcare, Diegem, Belgium), 300 nM forward and reverse primer, 50 nM dual-labelled probe and 1.25 U AmpliTaq Gold DNA Polymerase (Applied Biosystems). Using the ABI Prism 7700 Sequence Detector (Applied Biosystems), samples were heated at 951C for 10 min and amplified for 40 cycles at 951C for 15 s and 601C for 60 s in MicroAmp optical 96-well plates covered with MicroAmp optical seals (Applied Biosystems). PCR reactions performed on a serial dilution of pooled cDNA (human cell lines) indicated that the amplification efficiency for p73 and GAPDH primerprobe sets was above 96%. Relative mRNA levels of p73 isoforms are expressed in % of GAPDH and were calculated by the formula 2 ÀDCt Â 1000, in which DCt is the difference in Ct value at which copies of GAPDH and p73 isoforms become amplified fluorogenic measurable above baseline emission. 36 The mRNA expression of p73 isoforms was divided into three categories of level of detection: negative, no mRNA detected (0% of GAPDH); low, mRNA was detected but expression levels were extremely low (40% but p0.01% of GAPDH); high, mRNA was clearly expressed (40.01% of GAPDH). Table 1 Primer and probe sequences
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; M, methylated DNA sequence after bisulphite treatment; TA, transactivation; UM, unmethylated DNA sequence after bisulphite treatment.
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Methylation-specific PCR
An amount of 10 mg genomic DNA was denatured by the addition of sodium hydroxide to a final concentration of 0.2 M and incubation at 371C for 15 min. Subsequently, DNA was bisulphite treated by the addition of 200 ml bisulphite reaction mixture (5 M sodium bisulphite, 100 mM hydroquinone (Sigma), 0.35 M sodium hydroxide, pH ¼ 5.0) per microgram DNA and incubation at 501C for 4 h. Bisulphite-treated DNA was purified by the DNA clean-up Wizard kit (Promega, Leiden, The Netherlands) followed by the addition of sodium hydroxide to a final concentration of 0.3 M. DNA was precipitated by the addition of 1/10 volume of 3 M ammonium acetate, 1 ml glycogen (20 mg/ml; Roche), 100% ethanol and incubated at À201C for at least 30 min. Samples were centrifuged at 10 000 g and DNA pellets were washed twice with 70% ethanol. Bisulphite-treated DNA was dissolved in 40 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH ¼ 8.0) and stored at À801C. The methylation status of the p73 gene was analysed by methylation-specific PCR on the promoter regions from which mRNA of TA-p73, p73Dex2, p73Dex3, p73Dex2/3, DN 0 -p73 (all transcribed from the TA-promoter) and DN-p73 (transcribed from the alternative 3 0 -promoter) are expressed. Specific PCR primers for the detection of methylated and unmethylated DNA sequences in the TA-and alternative 3 0 -promoter of the p73 gene after bisulphite treatment are listed in Table 1 . PCR reactions were carried out in 50 ml volumes containing 0.5-1.0 mg bisulphite-treated DNA, 1 Â PCR buffer, 1.5-2 mM MgCl 2 (Integro), 200 mM of each dNTP (GE Healthcare), 300 nM forward and reverse primer and 1.25 U DNA Polymerase (Integro). Samples were heated to 951C for 5 min and amplified for 14 cycles at 941C for 20 s, 631C for 60 s (decrease of 0.51C per cycle) and 721C for 60 s. Subsequently, a second amplification was initiated for 20 cycles at 941C for 20 s, 561C for 60 s and 721C for 60 s. Samples were analysed on 2% agarose gel for the identification of PCR products.
LOH analysis
Microsatellite marker D1S468 was used to determine LOH at the 1p36.3 region. PCR primers for the amplification of D1S468 are listed in Table 1 . PCR reactions were performed in 50 ml volumes containing 60 ng genomic DNA, 1 Â PCR buffer II, 2 mM MgCl 2 (Applied Biosystems), 200 mM of each dNTP (GE Healthcare), 300 mM of forward and reverse primer and 1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems). Samples were heated to 951C for 5 min and amplified for 14 cycles at 941C for 20 s, 621C for 60 s (decrease of 0.51C per cycle) and 721C for 60 s. Subsequently, a second amplification was initiated for 20 cycles at 941C for 20 s, 551C for 60 s and 721C for 60 s. Aliquots of 10 ml of each PCR product were injected for separation by the WAVE-system 3500HT at 501C for 0-14.6 min (buffer B 45-65%). Output traces were individually examined in Navigator software (Transgenomic Transgenomic, Elancourt, France). LOH was defined as a reduced intensity of more than 50% of one peak compared to the second peak (second peak normalized to 100%).
Statistical analysis
The difference in frequency between groups of patients was statistically analysed by the w 2 -test (2/3 unordered groups, 2 df) or the w 2 trend -test (2/3 ordered groups, 1 df). All analyses were two-tailed and differences were considered statistically significant when Pp0.05. p73 isoforms in childhood T-ALL M Meier et al
Results
Differential expression of TA-p73 and DTA-p73 isoforms in childhood T-ALL mRNA levels of proapoptotic (TA-p73, i.e. total of TA isoforms) and antiapoptotic isoforms of p73 (DTA-p73, i.e. p73Dex2, p73Dex3, p73Dex2/3, DN-p73 and DN 0 -p73) were measured in leukaemic cells of 55 children with T-ALL and cells of 12 nonleukaemic paediatric controls. The total (TA þ DTA) level of p73 mRNA was high (40.01% of GAPDH) in 17 of 55 (31%) T-ALL patients compared to only one of 12 (8%) control cases (Figure 2a, P ¼ 0.004) . DTA-p73, but not TA-p73 was expressed at higher mRNA levels in T-ALL compared to healthy controls (Figure 2b , P ¼ 0.004 and P ¼ 0.37, respectively). In T-ALL, the relative contribution of DTA-p73 transcripts (88%) to the total level of p73 mRNA was larger than TA-p73 (12%, Figure 3 ). In addition, p73Dex2 and p73Dex2/3 were the most abundantly expressed antiapoptotic isoforms in T-ALL (Figure 3, 29 and 44%, respectively).
T-ALL cells derived from patients with high levels (40.01% of GAPDH) of total (TA þ DTA) p73 survive better at increasing concentrations of the DNA-damaging drug daunorubicin compared to cells with low levels or absence of p73 transcripts ( Figure 4 and Table 2 , P trend ¼ 0.045). A high expression of total (TA þ DTA) p73 did not relate to cell survival in the presence of increasing concentrations of prednisolone, vincristine and L-asparaginase (data not shown). Interestingly, exactly the same graph as in Figure 4 was observed when patients were divided in groups with a high, low or negative expression of DTA-p73 in their cells (Table 2 , P trend ¼ 0.045). No association was observed between different levels of TA-p73 mRNA and resistance of patient cells to daunorubicin ( Table 2 , P trend ¼ NS).
p73 transcripts were highly expressed in daunorubicinresistant cells of eight of 16 (50%) T-ALL patients ( Figure 5 , panel a) and in daunorubicin-sensitive cells of only two of 17 (12%) patients ( Figure 5, panel b) . In comparison with proapoptotic TA-p73, antiapoptotic DTA-p73 transcripts were more abundant and expressed at higher levels (71% of total p73 expression) in daunorubicin-resistant T-ALL cells ( Figure 5 , panel a, pie-chart). Interestingly, the antiapoptotic isoform p73Dex2 was highly represented in these leukaemic patient cells (44% of total p73 expression). The contribution of each TA-p73 ∆N/∆N'-p73 Figure 3 Relative expression of TA-p73 and DTA-p73 isoforms in childhood T-ALL. The percentage of each isoform represents the relative contribution of each isoform to the total level of p73 mRNA in leukaemic cells of 55 children with T-ALL. The contribution of proapoptotic TA-p73 to total p73 (12%) is less than the contribution of antiapoptotic DTA-p73 (88%, i.e. p73Dex2, p73Dex3, p73Dex2/3, DN-p73 and DN 0 -p73).
p73 isoforms in childhood T-ALL M Meier et al isoform to total p73 was not calculated for sensitive cells as expression of p73 was low or absent in the majority of these cases ( Figure 5, panel b) . Leukaemic cells of four of 11 (36%) T-ALL patients who relapsed show a high expression of p73 transcripts ( Figure 6,  panel a) . A high expression of p73 transcripts was also found in cells of nine of 38 (24%) T-ALL patients who remained in continuous complete remission ( Figure 6, panel b) . As seen in Table 2 , expression of total (TA þ DTA) p73, TA-p73 and DTAp73 mRNA did not significantly differ between T-ALL patients who did and did not relapse (P trend ¼ NS).
These results suggest that childhood T-ALL is associated with a high expression of antiapoptotic isoforms of p73 and the level of expression of these isoforms is associated with cellular resistance to DNA-damaging drugs in children at initial diagnosis of T-ALL.
LOH and methylation of p73 in childhood T-ALL
As the expression of p73 isoforms was below level of detection in 21 of 55 (38%) T-ALL patients, we investigated whether this could be explained by deletions of p73 or hypermethylation of its promoter region. LOH at chromosome locus 1p36.3 was detected in only 3/51 (5.9%) T-ALL patients suggesting that loss of p73 is a rare event in childhood T-ALL. In addition, we investigated the methylation status of both the TA-promoter (used for TA-p73, p73Dex2, p73Dex3, p73Dex2/3 and DN 0 -p73) and the alternative 3 0 -promoter (used for DN-p73 only) of p73 in genomic DNA samples of 44 T-ALL children compared to 12 paediatric and five adult controls. The TA-promoter was found to be methylated in 12 of 44 (27%) T-ALL patients but not in controls (P ¼ 0.02). The alternative 3 0 -promoter was found to be methylated in all patients and controls. Surprisingly, a methylated p73 gene was not restricted to T-ALL patients with negative or low expression of p73 isoforms, but also existed in patients with high mRNA levels of TA-p73 and DTA-p73 isoforms. These data suggest that methylation may not affect both alleles or occurs in a subpopulation of leukaemic cells and therefore does not explain the absence of p73 transcripts in 38% of children with T-ALL.
Discussion
p73 has found to be overexpressed in human cancers, including leukaemias such as B-cell chronic lymphoblastic leukaemia, chronic myeloid leukaemia, acute myeloid leukaemia and ALL. [26] [27] [28] [29] [30] [31] Since the discovery of DN-p73, studies have discriminated between proapoptotic (TA-p73) and antiapoptotic (DTA-p73) isoforms of p73 and pointed to an accumulation of DTA-p73 in human tumours. 15, [37] [38] [39] We demonstrate in this study that paediatric T-ALL is characterized by a high expression of p73 transcripts compared to control cases. The higher expression of p73 is mainly caused by a higher expression of DTA-p73 transcripts in T-ALL patients, in particular p73Dex2 and p73Dex2/3. This imbalance between TA and DTA isoforms may play a role in altered chemotherapeutic responses. TA-p73 is suggested to cooperate with wild-type p53 to induce genes that are essential for an appropriate cellular response to DNA damaging agents. 40, 41 Overexpression of DTA-p73 was shown to inhibit chemotherapy-induced apoptosis in tumour cells with Figure 4 Dose-response curve for daunorubicin of leukaemic cells derived from T-ALL patients with negative, low and high expression levels of total p73 mRNA. Leukaemic cells of children with T-ALL with a high level of total (TA þ DTA) p73 (n ¼ 10, x 2 ¼ 0.071 mg/ml) survive better at increasing concentrations of the DNA-damaging drug daunorubicin compared to cells with a low level (n ¼ 9) or absence (n ¼ 14) of total p73 (x 1 ¼ 0.035 mg/ml, P ¼ 0.045) (p73 is undetectable if mRNA expression is 0% of GAPDH (negative), low if 40% but p0.01% of GAPDH, high if 40.01% of GAPDH; x 1 , median daunorubicin LC 50 of patient cells with low þ negative p73; x 2 , median daunorubicin LC 50 of patient cells with high p73). wild-type p53. 11, 39 In addition, abrogation of TA-p73 function by expression of a dominant-negative mutant or silencing by RNA interference led to chemoresistance of tumour cells. 20, 40 The fact that antiapoptotic DTA-p73 proteins are shown to functionally inhibit wild-type p53 and TA-p73 may be an explanation for our finding that leukaemic cells of T-ALL patients with a high expression of DTA-p73 isoforms are more resistant to the DNA-damaging drug daunorubicin compared to cells with low or absence of these transcripts.
Casciano et al. 42 and Uramoto et al. 43 have shown that neuroblastoma and lung cancer patients with expression of DN-p73 show reduced survival compared to patients without expression of this isoform. Our data suggest that expression of DN-p73 and DN 0 -p73 as well as other antiapoptotic isoforms of p73 does not play a role in the increased relapse-risk of T-ALL patients as no difference in expression is observed between relapsed and nonrelapsed patients. However, the ratio between TA-p73 and DTA-p73 may be important to clinical outcome, but . Antiapoptotic isoforms (71% of total p73 expression), and in particular p73Dex2 (shaded, 44% of total p73 expression), were most abundantly expressed in daunorubicin-resistant cells (a, pie-chart). As p73 was not expressed in the majority of sensitive samples, a pie-chart including the relative frequency of isoform expression could not be made for sensitive samples (panel b). (p73 is undetectable if mRNA expression is 0% of GAPDH (negative), low if 40% but p0.01% of GAPDH, high if 40.01% of GAPDH; ND, not done; DNR, daunorubicin; neg, negative; DNR-resistant cases, 4median LC 50 ; DNR-sensitive cases, pmedian LC 50 ). TA-p73 Figure 6 Expression of TA-p73 and DTA-p73 isoforms in children with T-ALL who did and did not relapse. Leukaemic cells of four of 11 (36%) T-ALL patients who relapsed show a high expression of p73 transcripts (a). A high expression of p73 transcripts was also found in cells of nine of 38 (24%) T-ALL patients who remained in continuous complete remission (b). (p73 is undetectable if mRNA expression is 0% of GAPDH (negative), low if 40% but p0.01% of GAPDH, high if 40.01% of GAPDH; neg, negative).
p73 isoforms in childhood T-ALL M Meier et al the number of patients in this study was too small to investigate this issue. The frequency of T-ALL patients with absence of p73 mRNA in this study (38%) is consistent with other studies. [44] [45] [46] It was previously shown that inactivation and loss of expression of p73 owing to LOH or hypermethylation of its promoter is associated with haematological malignancies. [45] [46] [47] [48] For example, methylation of p73 was found in 26% of B-cell lymphomas and in 30% of ALL and Burkitt's lymphoma cases. 47, 48 Our results also show that p73 is methylated in 27% of T-ALL cases but not in healthy controls. However, we could not find an association between the methylation status of p73 and the level of p73 mRNA suggesting that the second allele may still be active or that methylation occurs in a subclone of leukaemic cells. Moreover, the lack of p73 transcripts in 38% of T-ALL children could not be explained by deletions of p73 as LOH was rarely observed. Additionally, it may be possible that expression of p73 mRNA is not regulated by methylation in these patient cells but by means of other mechanisms, for instance, through the post-transcriptional regulation by microRNAs. To date however, no such microRNAs for p73 have been identified.
In summary, our results suggest that childhood T-ALL is associated with a high expression of antiapoptotic isoforms of p73 and these isoforms may play a role in cellular resistance to DNA damaging drugs in children at initial diagnosis of T-ALL. The functional contribution of p73 to daunorubicin resistance awaits further studies.
